Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease (RISE)
A Multicenter Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Pegunigalsidase Alfa (PRX-102) in Japanese Patients With Fabry Disease (RISE)
Sponsor: Chiesi Farmaceutici S.p.A.
This PHASE2/PHASE3 trial investigates Fabry Disease and is currently actively recruiting participants. Chiesi Farmaceutici S.p.A. leads this study, which shows 12 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Recruiting PHASE2/PHASE3
-
May 2025 — Sep 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Nov 2024 — May 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2/PHASE3
▶ Show 7 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2023 — Mar 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Jun 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Mar 2023 — Jun 2023 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chiesi Farmaceutici S.p.A.
- ICON plc
For direct contact, visit the study record on ClinicalTrials.gov .